Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

(ARTICLE 223-16 OF GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY) (ARTICLE 223-16 OF GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY)

MONTHLY INFORMATION ON SHARE CAPITAL AND COMPANY VOTING RIGHTS

NEW YORK, JULY 30, 2026 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS- NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER 2026 ENDING JUNE 30, 2026 ON THURSDAY, AUGUST 6, 2026 AFTER THE CLOSE OF THE US MARKET.

CELLECTIS TO REPORT SECOND QUARTER FINANCIAL RESULTS ON AUGUST 6, 2026

EMERYVILLE, CALIF., JULY 15, 2026 (GLOBE NEWSWIRE) -- PROLYNX, A BIOTECHNOLOGY COMPANY DEVELOPING A NEXT-GENERATION PORTFOLIO OF ULTRA-LONG-ACTING MEDICINES FOR OBESITY AND RELATED METABOLIC CONDITIONS, TODAY ANNOUNCED TWO ADDITIONS TO ITS EXECUTIVE LEADERSHIP TEAM: SIMON HARNEST AS CHIEF FINANCIAL OFFICER AND AMER MIRZA, PHD, AS CHIEF SCIENTIFIC OFFICER.

PROLYNX NAMES SIMON HARNEST AS CHIEF FINANCIAL OFFICER AND AMER MIRZA, PHD, AS CHIEF SCIENTIFIC OFFICER AS IT ADVANCES MULTI-PROGRAM OBESITY AND METABOLIC DISEASE PORTFOLIO

NEW YORK, JUNE 25, 2026 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS- NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, HELD TODAY ITS SHAREHOLDERS GENERAL MEETING AT 2:30 P.M. CET AT THE BIOPARK AUDITORIUM, 11 RUE WATT, 4TH FLOOR, 75013 PARIS, FRANCE.

CELLECTIS REPORTS RESULTS FROM SHAREHOLDERS MEETING HELD ON JUNE 25, 2026

NEW YORK, JUNE 11, 2026 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, PRESENTS FINAL PHASE 1 DATA FROM THE BALLI-01 CLINICAL TRIAL EVALUATING LASME-CEL, A CD22 DIRECTED ALLOGENEIC CAR-T THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL), AND PRELIMINARY DATA FROM THE NATHALI-01 STUDY EVALUATING ETI-CEL, A DUAL CD20 AND CD22 DIRECTED CAR-T IN RELAPSED/REFRACTORY B-CELL NON HODGKIN LYMPHOMA (R/R B-NHL), AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2026 ANNUAL CONGRESS.

CELLECTIS PRESENTS FINAL PHASE 1 RESULTS OF LASME-CEL AND PRELIMINARY RESULTS ON ETI-CEL AT EHA 2026 CONGRESS

NEW YORK, JUNE 09, 2026 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION TO LASMECABTAGENE TIMGEDLEUCEL (LASME-CEL), ITS CD22-TARGETING ALLOGENEIC CAR-T CELL THERAPY PRODUCT CANDIDATE, FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL).

CELLECTIS RECEIVES FDA RMAT DESIGNATION FOR LASME-CEL, THE FIRST ALLOGENEIC CAR-T THERAPY IN A PIVOTAL TRIAL FOR PATIENTS WITH R/R B-ALL

PARIS, JUNE 03, 2026 (GLOBE NEWSWIRE) -- LISTING MARKET: EURONEXT GROWTH ISIN CODE: FR0010425595 DATE TOTAL NUMBER OF SHARES IN THE CAPITAL TOTAL NUMBER OF VOTING RIGHTS 05/31/2026 100,691,658 106,134,467 FOR FURTHER INFORMATION ON CELLECTIS, PLEASE CONTACT: MEDIA CONTACTS: PASCALYNE WILSON, DIRECTOR, COMMUNICATIONS, + 33 (0)7 76 99 14 33,MEDIA@CELLECTIS.COM PATRICIA SOSA NAVARRO, CHIEF OF STAFF TO THE CEO,+33 (0)7 76 77 46 93 INVESTOR RELATIONS CONTACT: ARTHUR STRIL, CHIEF FINANCIAL OFFICER & CHIEF BUSINESS OFFICER,INVESTORS@CELLECTIS.COM ATTACHMENTS VOTING_RIGHTS_PR_MAY_2026_EN

NEW YORK, MAY 20, 2026 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS- NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, ANNOUNCED TODAY THAT IT WILL HOLD ITS ANNUAL GENERAL MEETING ON JUNE 25, 2026 AT 2:30 P.M. CET AT THE BIOPARK AUDITORIUM, 11 RUE WATT, 4TH FLOOR, 75013 PARIS, FRANCE.

CELLECTIS' ANNUAL SHAREHOLDERS GENERAL MEETING TO BE HELD ON JUNE 25, 2026

NEW YORK, MAY 12, 2026 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY ANNOUNCED UPCOMING PRESENTATIONS ON THE BALLI-01 AND NATHALI-01 CLINICAL TRIALS, AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL CONGRESS, ON JUNE 11-14, 2026, IN STOCKHOLM, SWEDEN.

CELLECTIS TO PRESENT CLINICAL DATA ON LASME-CEL AND ETI-CEL AT EHA 2026 ANNUAL CONGRESS

PIVOTAL PHASE 2 WITH LASME-CEL IN R/R B-ALL (BALLI-01 TRIAL) PIVOTAL PHASE 2 FIRST INTERIM ANALYSIS EXPECTED IN Q4 2026 BLA SUBMISSION ANTICIPATED IN 2028 PHASE 1 WITH ETI-CEL IN R/R NHL (NATHALI-01 TRIAL) FULL PHASE 1 DATASET EXPECTED IN Q4 2026 INNOVATION PRECLINICAL DATA ON TALE-BASED EPIGENETIC EDITING, A NON-DNA CUTTING APPROACH, TO BE PRESENTED AT ASGCT SERVIER (THROUGH ALLOGENE): INTERIM PIVOTAL DATA REPORTED FROM THE ALPHA3 TRIAL OF CEMA-CEL (N=24) 58.3% OF PATIENTS IN THE CEMA-CEL ARM ACHIEVED MRD NEGATIVITY VERSUS 16.7% IN THE OBSERVATION ARM FAVORABLE SAFETY PROFILE: NO CASES OF CRS, ICANS, GVHD, OR TREATMENT-RELATED SERIOUS ADVERSE EVENTS STUDY ACCRUAL EXPECTED TO BE COMPLETED BY YEAR-END 2027, INTERIM EFS ANALYSIS IN MID-2027, PRIMARY EFS ANALYSIS IN MID-2028 CASH, CASH EQUIVALENTS AND FIXED-TERM DEPOSITS OF$188MILLION AS OF MARCH 31, 2026 1 PROVIDE RUNWAY INTOQ4 2027 NEW YORK, MAY 11, 2026 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY PROVIDED FINANCIAL RESULTS FOR THE FIRST QUARTER 2026, ENDING MARCH 31, 2026 AND PROVIDED A BUSINESS UPDATE. "THE INTERIM PIVOTAL DATA PUBLISHED BY ALLOGENE ON CEMA-CEL, A PRODUCT ORIGINALLY DEVELOPED BY CELLECTIS AS UCART19, ARE A PROUD VALIDATION OF OUR VISION: THAT ALLOGENEIC, OFF-THE-SHELF CELL THERAPY CANDIDATES COULD DELIVER TRANSFORMATIVE OUTCOMES FOR CANCER PATIENTS.

Cellectis S.A.

CLLS

Price

Financial Reports

No items found.

Press Releases

Cellectis S.A.

CLLS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CLLS